Holen Sie sich die Stockscreener-App
170.44
1.67%
2.80
Handel nachbörslich:
170.44
Schlusskurs vom Vortag:
$167.64
Offen:
$167.56
24-Stunden-Volumen:
1.73M
Relative Volume:
1.70
Marktkapitalisierung:
$8.39B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
21.28
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+4.73%
1M Leistung:
-13.50%
6M Leistung:
+24.65%
1J Leistung:
-12.94%
1-Tages-Spanne:
$167.45
$171.72
1-Wochen-Bereich:
$156.72
$172.39
52-Wochen-Spanne:
$91.86
$203.01
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
170.44 | 8.25B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc.CRL - The AI Journal
What Makes Charles River Laboratories (CRL) an Investment Bet? - Insider Monkey
How Does Charles River (CRL) Balance Cautious Guidance with Outperforming Q3 Results? - simplywall.st
Does Charles River’s Lowered Guidance After a Strong Quarter Signal Shifting Priorities for CRL? - Yahoo Finance
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Barclays Maintains Charles River Laboratories International (CRL) Overweight Recommendation - MSN
Charles River Laboratories Stock: Is Wall Street Bullish or Bearish? - MSN
Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT - MSN
Will Charles River Laboratories International Inc. stock outperform Dow JonesCPI Data & Reliable Breakout Forecasts - newser.com
Will Charles River Laboratories International Inc. stock benefit from Fed rate cutsEntry Point & Weekly High Potential Alerts - newser.com
Is Charles River Laboratories International Inc. stock undervalued by metricsMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
CRLCharles Riv Labs Intl Inc Latest Stock News & Market Updates - Stock Titan
Will Charles River Laboratories International Inc. stock see PE expansionJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
How Charles River Laboratories International Inc. (RV6) stock valuation compares with sectorTrade Volume Report & Low Risk Profit Maximizing Plans - newser.com
Using RSI to spot recovery in Charles River Laboratories International Inc.Weekly Trade Report & Weekly Breakout Watchlists - newser.com
What does recent volatility data suggest for Charles River Laboratories International Inc.Entry Point & Advanced Technical Signal Analysis - newser.com
Will Charles River Laboratories International Inc. (RV6) stock announce special dividendJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - newser.com
How strong is Charles River Laboratories International Inc. (RV6) stock earnings growthMarket Activity Recap & Real-Time Market Trend Scan - newser.com
Is Charles River Laboratories International Inc. stock attractive for dividend growthJuly 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
Can Charles River Laboratories International Inc. (RV6) stock deliver consistent EPS growth - newser.com
Charles River Laboratories International (MEX:CRL) Total Pa - GuruFocus
Charles River Laboratories International Stock: High Cash FlowWhy Not Watch It? - Trefis
Will Charles River Laboratories International Inc. stock see valuation expansion2025 Price Action Summary & Low Risk Entry Point Tips - newser.com
Visual analytics tools that track Charles River Laboratories International Inc. performanceJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - newser.com
Will Charles River Laboratories International Inc. stock benefit from green energy trends2025 Macro Impact & Daily Entry Point Trade Alerts - newser.com
Is Charles River Laboratories International Inc. stock vulnerable to rate hikesWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
Charles River Laboratories gets all-clear in monkey smuggling probe - NBC Boston
Charles River Laboratories gets all-clear from SEC in monkey smuggling probe - The Business Journals
Charles River Laboratories (CRL): Assessing Valuation After Latest Share Price Pullback - simplywall.st
Transcript : Charles River Laboratories International, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 11 - MarketScreener
CRL: Biotech bookings rebound, pricing stabilizes, and cost-saving drives margin protection - TradingView
Charles River (CRL) International Revenue Performance Explored - sharewise.com
Quick ratio of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView
Will Charles River Laboratories International Inc. (RV6) stock split increase liquidityGold Moves & Risk Controlled Stock Alerts - newser.com
What macro factors could drive Charles River Laboratories International Inc. (RV6) stock higher2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Charles River Laboratories, US SEC end investigations into primate shipments - MLex
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):